Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

New Data Cast Doubt On Gilead's Phase III NASH Candidate Selonsertib

Apr 20 2018

• By Joseph Haas

scientists doing lab research on digital screen

Related Content

Stealthy NGM And Bristol Emerge As Serious NASH Competitors

Apr 25 2017

Genfit's Enrollment Delay In NASH May Aid Intercept's First-To-Market Goal

Apr 25 2017

Madrigal's Early Phase IIb NASH Data Show Clinically Meaningful Fat Reduction

Dec 06 2017

Genfit May Be Gaining An Edge In NASH Race

Oct 26 2017

Gilead Data Suggest Role For ACC Inhibition In NASH

Oct 24 2017

The NASH Pipeline: Replete With Targets And New Compounds

Aug 29 2016

Intercept Increases Chance Of Success In NASH Without Significant Delay

Feb 10 2017

Intercept’s NASH Phase III Enrolling Slowly; Gilead Could Gain Ground

Jan 13 2017

Related Companies

Gilead Sciences, Inc.

NGM Biopharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.

Intercept Pharmaceuticals, Inc.

Genfit SA

Allergan plc

Pfizer Inc.

Novartis AG

Roche Holding AG

Additional Topics

Research & Development Business Strategies Clinical Trials Companies Liver & Hepatic BioPharmaceutical

More from R&D

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window